Skip to main content

A Mystery in the 'Tea for Two' Lyrics

Image result for nuclear family clipart

The Song "Tea for Two" has been around for a long time. More than 90 years in fact.

It was composed for the Broadway musical No No Nanette, which premiered on Broadway in 1925 after a run in Chicago the previous year (the traditional pre-Broadway shakedown cruise).

"Tea for Two" is a second act song, sung by Tom and Nanette, a couple that quarreled and broke up in Act I, but that has now reconciled. And as you surely know, since anybody who could possibly be reading this knows the lyrics to the song, Tom and Nanette are dreamily contemplating their future.

"We will raise a family
A boy for you a girl for me
Can't you see how happy we would be? 

We three..."

That is how it is often sung, anyway: in the Anita O'Day recording for example.

But, much as I love O'Day, this always pulls me up short. Surely the natural way to hear the second of those lines is for an "AND" to be implied. Nanette is dreaming of having two children with Tom. 

So, why "we three"? That only makes sense if one inserts an OR instead of an AND in the second line. Which seems counter-intuitive, given the blissful state Nanette is supposed to be in at the time. Her bliss is qualified by a disinclination to give birth twice? 


Comments

Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.



We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

Hume's Cutlery

David Hume is renowned for two pieces of cutlery, the guillotine and the fork.

Hume's guillotine is the sharp cut he makes between "is" statements and "ought" statements, to make the point that the former never ground the latter.

His "fork" is the division between what later came to be called "analytic" and "synthetic" statements, with the ominous observation that any books containing statements that cannot be assigned to one or the other prong should be burnt.

Actually, I should acknowledge that there is some dispute as to how well or poorly the dichotomy Hume outlines really maps onto the analytic/synthetic dichotomy. Some writers maintain that Hume meant something quite different and has been hijacked. Personally, I've never seen the alleged difference however hard they've worked to point it out to me.

The guillotine makes for a more dramatic graphic than a mere fork, hence the bit of clip art above.

I'm curious whe…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…